[1] Roth J A, Grammer S F, Swisher S G, et al. Gene replacement strategies for treating non-small cell lung cancer [J]. Semin Radiat Oncol, 2000, 10(4): 333-342.
[2] 张红梅, 孙秀华. 重组人p53腺病毒制品在肿瘤治疗中的研究进展[J]. 国际肿瘤学杂志, 2007, 34(11): 819-821.
[3] Lane D P. Cancer. p53, guardian of the genome [J]. Nature, 1992, 358(6381): 15-16.
[4] Shiraishi K, Kato S, Han S Y, et al. Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library[J]. J Biol Chem, 2004, 279(1):348-355.
[5] Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs [J]. J Exp Med, 1998, 188(11): 2033-2045.
[6] Bouvard V, Zaitchouk T, Vzcher M, et al. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice [J]. Oncogene, 2000, 19(5): 649-660.
[7] Chipuk J E, Kuwana T, Bouchier L, et al. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis [J]. Science, 2004, 303(5660):1010-1014.
[8] Leu J I, Dumont P, Hafey M, et al. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex [J]. Nat Cell Biol, 2004, 6(5): 443-450.
[9] Bennett M, Macdonald K, Chan S W, et al. Cell surface trafficking of fas: a rapid mechanism of p53-mediated apoptosis [J]. Science, 1998, 282(5387): 290-293.
[10] Yen N, Ioannides C G, Xu K, et al. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53) [J]. Cancer Gene Ther, 2000, 7(4):530-536.
[11] Cerwenka A, Lanier L L. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer [J]. Tissue Antigens, 2003, 61(5): 335-343.
[12] Sah N K, Munshi A, Nishikawa T, et al. Adenovirus-mediated wild-type p53 radiosensitizes human tumor cells by suppressing DNA repair capacity [J]. Mol Cancer Ther, 2003, 2(11): 1223-1231.
[13] Krishna R, Mayer L D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J]. Eur J Pharm Sci, 2000, 11(4): 265-283.
[14] Singh B, Reddy P G, Goberdhan A, et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas [J]. Genes Develop, 2002, 16(8): 984-993.
[15] Schwartzenberg F, Armoni M, Karneli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression [J]. Cancer Res, 2004,64: 2627-2633.
[16] Brasseur G, Tron P, Dujardin G, et al. The nuclear ABC1 gene is essential for the correct conformation and functioning of the cytochrome bc1 complex and the neighbouring complexes II and IV in the mitochondrial respiratory chain[J]. Eur J Biochem, 1997, 246: 103-111.
[17] Dameron K M, Volpert O V, Tainsky M A, et al. Control of angiogenesis　in fibroblasts by p53 regulation of thrombospondin-1 [J]. Science, 1994, 265(5178):1582–1584.
[18] Toschi E, Rotar R, Antonni A, et al. Wild-Type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells [J]. J Inv Dermatol, 2000, 114:1188-1194.
[19] Wilson D R, Introgen Therapeutics. Evaluation of biodistribution/transmission of gene therapy vectors [J]. Eur J Biochem, 2012, 264: 143-151.
[20] Swisher S G, Roth J A. Clinical update of Ad-p53 gene therapy for lung cancer [J]. Surg Oncol Clin N Am, 2002, 11(3): 521-535.
[21] Frederick F L, Janet M B, Gregory N F, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results [J]. J Clin Oncol, 2003, 21(13): 2508-2518.
[22] Nemunaitis J, Khuri F, Ganly I, et al. Phase Ⅱ trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer [J]. J Clin Oncol, 2001, 19(2): 289-298.
[23] Buller R E , Runnebaum I B, Karlan B Y,et al. A phase Ⅰ/Ⅱ trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer [J]. Cancer Gene Therapy, 2002, 9(3): 553-566.
[24] 韩德民,黄志刚,张 伟,等. 重组人p53 腺病毒注射液治疗喉癌的Ⅰ期临床试验及追踪观察[J]. 中华医学杂志, 2003, 83(23): 2029-2032.
[25] Sublett R. Introgen Therapeutics. Absence of RCA isolated from patients treated with INGN 201 (Ad5CMV-p53)[EB/OL]. http://www.fda.gov/ohrms/dockets/ac/01/slides /3768s104Sublett/ tsld001.htm
[26] 束永前, 王朝霞. 重组腺病毒p53 基因治疗肺癌的研究进展[J]. Chin J Lung Cancer, 2005, 8(2): 148-151.
[27] Zumstein L A, Call D, Merritt J, et al. Safety of adenoviral vectors: results of clinical investigations in 445 cancer patients treated with advexin? (Adenoviral p53) gene therapy[C]. 7th annual meeting of ASGT Abstract 1007#. 2004, June 6.
[28] Schuler M, Rochlitz C, Horowitz J A, et al. A phase Ⅰ study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer [J]. Hum Gene Ther, 1998, 9(14):2075-2082.
[29] Weill D, Mack M, Roth J, et al. Adenoviral-mediated p53 gene transfer to non-small cell lung cancer through endobronchial injection [J]. Chest, 2000,118(4):966-970.
[30] Kauczor H U, Schuler M, Heussel C P, et al. CT2 guided intratumoral gene therapy in non-small cell lung cancer [J]. Eur Radiol, 1999, 9(2) :292-296.
[31] Swisher S G, Roth J A, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer [J]. J Natl Cancer Inst, 1999, 91(9):763-771.
[32] Carbone D P, Adak K, Schiller J, et al. Adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioalveolar cell lung carcinoma (BAC)[abstract][J]. Proc Am Soc Clin Oncol, 2003, 22: 620a.
[33] Schuler M Herrmann R, De Greve J L, et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer: results of a multicenter phase Ⅱ study [J]. J Clin Oncol, 2001, 19 (6):1750-1758.
[34] Swisher S G, Roth J A, Komaki R, et al. A phase Ⅱ trial of adenoviral mediated p53 gene transfer ( RPR/ INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC)[ abstract ][J]. Proc Am Soc Clin Oncol,2000,19:461a.
[35] Swisher S G, Roth J A, Komaki R, et al. Induction of p53 regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (IN2 GN 201) and radiation therapy [J]. Clin Cancer Res, 2003, 9(1):93-101.
[36] 官泳松,刘 源,贺 庆,等. p53基因(今又生(R))联合支气管动脉化疗治疗肺癌15例近期疗效观察[J]. 中国介入影像与治疗学,2005, 2(6): 405-408.
[37] 田 耕,翁 准,覃天力, 等. 重组人 p53 腺病毒治疗晚期非小细胞肺癌的并发症分析[J]. 实用临床医学, 2006,7(4):96-98.
[38] 翁 准,覃天力,谭淑瑜,等. 瘤内注射重组人腺病毒治疗晚期肺癌临床试验观察[J]. 深圳中西医结合杂志, 2004(8):206-210.
[39] 刘艳华,孙 丽,孙三元. 今又生联合化疗治疗晚期非小细胞肺癌的安全性和近期疗效观察[J]. 齐齐哈尔医学院学报, 2015,36(36):5470-5472.
[40] Modesitt S C, Ramirez P, Zu Z, et al. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer [J]. Clin Cancer Res, 2001,7(6):1765-1772.